Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine

Leukemia. 2011 Dec;25(12):1910-3. doi: 10.1038/leu.2011.170. Epub 2011 Jul 15.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / therapeutic use*
  • DNA Methylation*
  • DNA-Binding Proteins / genetics*
  • Dioxygenases
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Prognosis
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Retrospective Studies
  • Risk Factors
  • Survival Rate

Substances

  • Antimetabolites, Antineoplastic
  • BCL2-like 10 protein
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Dioxygenases
  • TET2 protein, human
  • Azacitidine